Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

A case of vancomycin-induced drug hypersensitivity syndrome

반코마이신 투여 후 발생한 약물 과민성 증후군 1예

  • Min, Kyung Sun (Department of Pediatrics, Chonnam National University Medical School) ;
  • Choi, Woo Yeon (Department of Pediatrics, Chonnam National University Medical School) ;
  • Song, Eun Song (Department of Pediatrics, Chonnam National University Medical School) ;
  • Han, Dong Kyun (Department of Pediatrics, Chonnam National University Medical School) ;
  • Cho, Young Kuk (Department of Pediatrics, Chonnam National University Medical School) ;
  • Ma, Jae Sook (Department of Pediatrics, Chonnam National University Medical School)
  • 민경선 (전남대학교 의과대학 소아과학교실) ;
  • 최우연 (전남대학교 의과대학 소아과학교실) ;
  • 송은송 (전남대학교 의과대학 소아과학교실) ;
  • 한동균 (전남대학교 의과대학 소아과학교실) ;
  • 조영국 (전남대학교 의과대학 소아과학교실) ;
  • 마재숙 (전남대학교 의과대학 소아과학교실)
  • Received : 2008.03.27
  • Accepted : 2008.09.10
  • Published : 2008.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

Drug hypersensitivity syndrome (DHS) has rarely been reported in association with vancomycin treatment. Here, we describe an 11-year-old girl who developed fever and a maculopapular rash on day 18 of intravenous vancomycin for treatment of infective endocarditis. The patient presented with fever, a maculopapular skin rash, hepatitis, and acute renal failure caused by vancomycin-induced DHS. The symptoms resolved in less than 24 h after withdrawal of vancomycin and treatment with corticosteroids. We present this case of DHS associated with vancomycin.

반코마이신 투여 후에 발생하는 약물 과민성 증후군은 아주 드물게 보고되고 있다. 저자들은 11세 여자 환아에서 감염성 심내막염에 대한 치료로 반코마이신을 투여한 후 18일째부터 발열, 반구진성 발진이 관찰되어, 반코마이신 투여 중단 및 코르티코스테로이드를 투여한 지 24시간 이내에 임상 증상의 호전을 보인 약물 과민성 증후군 1예를 경험하였다. 본 증례의 환아에서는 발열, 반구진성 발진, 간염, 급성 신부전 등이 약물 과민성 증후군의 증상으로 관찰되었다.

Keywords

References

  1. Sullivan JR, Shear NH. The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001;137:357-64
  2. Yazganoglu KD, Ozkaya E, Ergin-Ozcan P, Cakar N. Vancomycin- induced drug hypersensitivity syndrome. J Eur Acad Dermatol Venereol 2005;19:648-50 https://doi.org/10.1111/j.1468-3083.2005.01228.x
  3. Hannah BA, Kimmel PL, Dosa S, Turner ML. Vancomycininduced toxic epidermal necrolysis. South Med J 1990;83: 720-2 https://doi.org/10.1097/00007611-199006000-00035
  4. Forrence EA, Goldman MP. Vancomycin-associated exfoliative dermatitis. DICP 1990;24:369-71 https://doi.org/10.1177/106002809002400405
  5. Hsu SI. Biopsy-proved acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy 2001;21:1233-9 https://doi.org/10.1592/phco.21.15.1233.33901
  6. Maki DG, Bohn MJ, Stolz SM, Kroncke GM, Acher CW, Myerowitz PD. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. J Thorac Cardiovasc Surg 1992;104:1423-34
  7. Romanelli VA, Howie MB, Myerowitz PD, Zvara DA, Rezaei A, Jackman DL, et al. Intraoperative and postoperative effects of vancomycin administration in cardiac surgery patients: a prospective, double-blind, randomized trial. Crit Care Med 1993;21:1124-31 https://doi.org/10.1097/00003246-199308000-00009
  8. Bayer AS. Infective endocarditis. Clin Infect Dis 1993;17: 313-22 https://doi.org/10.1093/clinids/17.3.313
  9. Litt JZ. Drug Eruption Reference Manual 2000. New York: Parthenon Publishing Group, 2000:591-2
  10. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8:5
  11. Handfield-Jones SE, Jenkins RE, Whittaker SJ, Besse CP, McGibbon DH. The anticonvulsant hypersensitivity syndrome. Br J Dermatol 1993;129:175-7 https://doi.org/10.1111/j.1365-2133.1993.tb03523.x
  12. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155:2285-90 https://doi.org/10.1001/archinte.155.21.2285
  13. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003;68:1781-90
  14. Kwon HS, Chang YS, Jeong YY, Lee SM, Song WJ, Kim HB, et al. A case of hypersensitivity syndrome to both vancomycin and teicoplanin. J Korean Med Sci 2006;21:1108-10 https://doi.org/10.3346/jkms.2006.21.6.1108
  15. Alqdah M, Al-Hihi E. Bullous skin eruption: A rare immune- mediated reaction to vancomycin. Chest 2006;130(3 Suppl):337S-9S
  16. Marius R. Drug hypersensitivity syndrome. DermNet NZ 2006. Available from:URL://http://www.dermnetnz.org/reactions/drug-hypersensitivity-syndrome.html
  17. Polk RE, Israel D, Wang J, Venitz J, Miller J, Stotka J. Vancomycin skin tests and prediction of "red man syndrome" in healthy volunteers. Antimicrob Agents Chemother 1993;37:2139-43 https://doi.org/10.1128/AAC.37.10.2139
  18. Anne S, Middleton E Jr, Reisman RE. Vancomycin anaphylaxis and successful desensitization. Ann Allergy 1994;73: 402-404
  19. Baden LA, Apovian C, Imber MJ, Dover JS. Vancomycininduced linear IgA bullous dermatosis. Arch Dermatol 1988; 124:1186-8 https://doi.org/10.1001/archderm.124.8.1186
  20. Vidal C, Gonzlez Quintela A, Fuente R. Toxic epidermal necrolysis due to vancomycin. Ann Allergy 1992;68:345-7
  21. Korman TM, Turnidge JD, Grayson ML. Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J Antimicrob Chemother 1997;39:371-81 https://doi.org/10.1093/oxfordjournals.jac.a020861